Global Bipolar Disorder Market

Bipolar Disorder Market Size, Share, Growth Analysis, By Type (Mood stabilizer, Anticonvulsants), By Drug Class (Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35I2095 | Region: Global | Published Date: January, 2025
Pages: 157 |Tables: 67 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Bipolar Disorder Market size was valued at USD 5.49 Billion in 2024 and is poised to grow from USD 5.62 Billion in 2025 to USD 6.8 Billion by 2033, growing at a CAGR of 2.4% during the forecast period (2026–2033).

    Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Eli Lilly and Company (USA) ', 'GlaxoSmithKline plc (UK) ', 'Pfizer Inc. (USA) ', 'AstraZeneca plc (UK) ', 'Otsuka Holdings Co., Ltd. (Japan) ', 'H. Lundbeck A/S (Denmark) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AbbVie Inc. (USA) ', 'Novartis International AG (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Bristol Myers Squibb Company (USA) ', 'Alkermes plc (Ireland) ', 'Mylan N.V. (USA) ', 'Neurocrine Biosciences, Inc. (USA) ', 'Vanda Pharmaceuticals Inc. (USA) ', 'Sunovion Pharmaceuticals Inc. (USA) ', 'Intra-Cellular Therapies, Inc. (USA) ', 'Acadia Pharmaceuticals Inc. (USA) ', 'Reviva Pharmaceuticals Holdings, Inc. (USA)'

    The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.

    Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.

    Geographically, North America is anticipated to dominate the global bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the global market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

    Related Reports

    Mental Health Market
    Buy Now GET FREE SAMPLE
    Lithium Market
    Buy Now GET FREE SAMPLE
    Sleep Disorder Market
    Buy Now GET FREE SAMPLE
    Mental Health Software Market
    Buy Now GET FREE SAMPLE
    FMD Disease Market
    Buy Now GET FREE SAMPLE
    Bipolar Junction Transistors (BJTs) Market
    Buy Now GET FREE SAMPLE
    Schizophrenia Drugs Market
    Buy Now GET FREE SAMPLE
    Behavioral Mental Health Software Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Bipolar Disorder Market

    Report ID: SQMIG35I2095

    $5,300
    BUY NOW